1
|
Kang X, Zhu N, Song X. [Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2017; 19:711-714. [PMID: 27760604 PMCID: PMC5973409 DOI: 10.3779/j.issn.1009-3419.2016.10.13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer (NSCLC), drugs targeting epidermal growth factor receptor (EGFR) has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors targeted at BRAF gene have obviously clinical efficacy to specific advantages populations with little side-effect, and be well tolerated. It is discovered recently that drug resistance also exists in BRAF inhibitors like other targeted drugs, the mechanism of drug resistance is being studied. In this paper, a review were performed in the mechanism, clinical application, adverse reactions and the drug resistance of BRAF inhibitors.
Collapse
Affiliation(s)
- Xiaoyan Kang
- Department of Respiratory, Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China
| | - Nan Zhu
- Department of Gastroenterology, Shanxi Province People's Hospital, Taiyuan 030012, China
| | - Xia Song
- Department of Respiratory, Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China
| |
Collapse
|
2
|
李 亚, 周 云, 王 洪. [Research status on molecular targeted therapy for squamous-cell lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2014; 17:618-24. [PMID: 25130969 PMCID: PMC6000367 DOI: 10.3779/j.issn.1009-3419.2014.08.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 06/25/2014] [Indexed: 11/25/2022]
Abstract
Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently. Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%. The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study. SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials. In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC.
Collapse
Affiliation(s)
- 亚楠 李
- />100028 北京,北京煤炭总医院肿瘤内科Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China
| | - 云芝 周
- />100028 北京,北京煤炭总医院肿瘤内科Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China
| | - 洪武 王
- />100028 北京,北京煤炭总医院肿瘤内科Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China
| |
Collapse
|
3
|
Zhang HP, Pan JB, Zhang C, Ji N, Wang H, Ji ZL. Network understanding of herb medicine via rapid identification of ingredient-target interactions. Sci Rep 2014; 4:3719. [PMID: 24429698 PMCID: PMC3893644 DOI: 10.1038/srep03719] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Accepted: 12/19/2013] [Indexed: 01/03/2023] Open
Abstract
Today, herb medicines have become the major source for discovery of novel agents in countermining diseases. However, many of them are largely under-explored in pharmacology due to the limitation of current experimental approaches. Therefore, we proposed a computational framework in this study for network understanding of herb pharmacology via rapid identification of putative ingredient-target interactions in human structural proteome level. A marketing anti-cancer herb medicine in China, Yadanzi (Brucea javanica), was chosen for mechanistic study. Total 7,119 ingredient-target interactions were identified for thirteen Yadanzi active ingredients. Among them, about 29.5% were estimated to have better binding affinity than their corresponding marketing drug-target interactions. Further Bioinformatics analyses suggest that simultaneous manipulation of multiple proteins in the MAPK signaling pathway and the phosphorylation process of anti-apoptosis may largely answer for Yadanzi against non-small cell lung cancers. In summary, our strategy provides an efficient however economic solution for systematic understanding of herbs' power.
Collapse
Affiliation(s)
- Hai-Ping Zhang
- 1] State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361102, PR China [2]
| | - Jian-Bo Pan
- 1] Department of Chemical Biology, College of Chemistry and Chemical Engineering, The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, Fujian, 361005, PR China [2]
| | - Chi Zhang
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361102, PR China
| | - Nan Ji
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361102, PR China
| | - Hao Wang
- Department of Chemical Biology, College of Chemistry and Chemical Engineering, The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, Fujian, 361005, PR China
| | - Zhi-Liang Ji
- 1] State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361102, PR China [2] Department of Chemical Biology, College of Chemistry and Chemical Engineering, The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen, Fujian, 361005, PR China
| |
Collapse
|